The Community Practice Research Core, formerly the Community Practice Core, enables Dana-Farber/Harvard Cancer Center researchers to conduct cancer-related projects in real-world community settings. The Core provides easy access to a racially diverse population of over 11,000,000 patients within the local and national community-based clinical practices of Harvard Vanguard Medical Associates (HVMA)/Atrius Health, Harvard Pilgrim Health Care and HMO Cancer Research Network. Harvard Vanguard Medical Associates is a non-profit, multi-specialty medical group practice providing care to more than 480,000 adult and pediatric patients at over 21 offices across eastern Massachusetts. It is one of five medical groups that comprise Atrius Health. All Atrius groups share a single electronic medical record system (EPIC?), easing researchers'access to its 600,000 patients. Harvard Pilgrim Health Care is a non-profit health plan that provides medical insurance to more than 1,000,000 members in Massachusetts, New Hampshire and Maine. Cancer Research Network is an NCI-funded consortium of 14 integrated healthcare systems, representing 11,000,000 enrollees across the United States. This facility has been continuously funded by the CCSG since 2000. Director: Larissa Nekhlyudov, MD, MPH(HMS) Category: 3.01, 3.03 and 3.06 (Population Research) Management: Cancer Center managed.

Public Health Relevance

The Core conducts research on cancer prevention, detection, treatment, long-term care, surveillance and survivorship. The populations that this core accesses are ideal for studies that involve basic, clinical and population sciences that address issues impacting diverse communities;need large samples of patients and/or providers;examine preventive strategies;include rare cancers;investigate the dissemination of proven technologies and interventions;and focus on cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601498
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$169,466
Indirect Cost
$60,776
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications